10P Proximal Deletions from 10P11 and 10P12 FTNP
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Ring Finger 20/Ring Finger 40/WW Domain‑Containing Adaptor with Coiled‑Coil Complex Interacts with P53 to Regulate Gene Transcription in DNA Damage Response
ONCOLOGY LETTERS 21: 436, 2021 Ring finger 20/ring finger 40/WW domain‑containing adaptor with coiled‑coil complex interacts with p53 to regulate gene transcription in DNA damage response DANNI MENG*, KUN GUO*, DIE ZHANG*, CHENG ZHAO, CHUANWEN SUN and FENG ZHANG College of Life Sciences, Shanghai Normal University, Shanghai 200234, P.R. China Received January 19, 2020; Accepted December 17, 2020 DOI: 10.3892/ol.2021.12697 Abstract. p53 is one of the most important tumor suppressor the results of the present study revealed the molecular mecha‑ genes, and its primary function is to act as a transcriptional nism of the interaction between the RNF20/RNF40/WAC activator to control cell cycle arrest, DNA repair and cellular complex and p53, and demonstrated that these proteins regu‑ metabolism by recognizing and binding to specific DNA lated gene transcription in the DNA damage response. sequences. Defects in the ring finger (RNF)20/RNF40/WW domain‑containing adaptor with coiled‑coil (WAC) complex, Introduction one of the histone H2B ubiquitination E3 ligases, have been reported to be a key factor in oncogenesis, cancer cell migra‑ p53 is a tumor suppressor protein (1). Mutations within p53 tion and invasion. Histone H2B mono‑ubiquitination has been have been demonstrated to lead to its inactivation, which is demonstrated to be essential for maintaining the functionality associated with ~50% of all types of human cancer (2). The p53 of the p53 tumor suppressor protein. The aim of the present protein contains an amino N‑terminal transactivation domain, study was to identify any sites in the p53 DNA‑binding a proline‑rich domain, a central DNA‑binding domain (DBD), domain (DBD) specific to the RNF20/RNF40/WAC a tetramerization domain and a carboxy‑terminal regulatory complex that may be involved in the gene regulation in DNA domain (CRD) (3). -
GOLGA2/GM130 Is a Novel Target for Neuroprotection Therapy in Intracerebral Hemorrhage
GOLGA2/GM130 is a Novel Target for Neuroprotection Therapy in Intracerebral Hemorrhage Shuwen Deng Second Xiangya Hospital Qing Hu Second Xiangya Hospital Qiang He Second Xiangya Hospital Xiqian Chen Second Xiangya Hospital Wei Lu ( [email protected] ) Second Xiangya Hospital, central south university https://orcid.org/0000-0002-3760-1550 Research Article Keywords: Golgi apparatus, therapy, intracerebral hemorrhage, autophagy, blood–brain barrier Posted Date: June 1st, 2021 DOI: https://doi.org/10.21203/rs.3.rs-547422/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/25 Abstract Blood–brain barrier (BBB) impairment after intracerebral hemorrhage (ICH) can lead to secondary brain injury and aggravate neurological decits. Currently, there are no effective methods for its prevention or treatment partly because of to our lack of understanding of the mechanism of ICH injury to the BBB. Here, we explored the role of Golgi apparatus protein GM130 in the BBB and neurological function after ICH. The levels of the tight junction-associated proteins ZO-1 and occludin decreased, whereas those of LC3-II, an autophagosome marker, increased in hemin-treated Bend.3 cells (p < 0.05). Additionally, GM130 overexpression increased ZO-1 and occludin levels, while decreasing LC3-II levels (p < 0.05). GM130 silencing reversed these effects and mimicked the effect of hemin treatment (p < 0.05). Moreover, tight junctions were disrupted after hemin treatment or GM130 silencing and repaired by GM130 overexpression. GM130 silencing in Bend.3 cells increased autophagic ux, whereas GM130 overexpression downregulated this activity. Furthermore, GM130 silencing-induced tight junction disruption was partially restored by 3-methyladenine (an autophagy inhibitor) administration. -
Acute Lymphoblastic Leukemia in Pediatric Epigenetic Approach
MOJ Anatomy & Physiology Research Article Open Access Acute lymphoblastic leukemia in pediatric epigenetic approach Abstract Volume 7 Issue 4 - 2020 Introduction and objectives: Acute lymphoblastic leukemia (ALL) in pediatric patients Jose Ignacio Pat Yeh,1 Pedro Emmanuel Poot is an issue that affects the quality of life of the patient and his family, so it is urgent to 1 2 know the physiology, presentation, and functionality of the cell population that allows Chable, Abner Ismael Guzman Félix, Luis 2 3 determining the more effective treatments. The objective is to review the evidence derived Sandoval Jurado, David Rojano-Mejía, from cohort studies and clinical trials on ALL in pediatric patients. Jiménez Báez María Valeria3 1Student of the Bachelor of Medicine, University of Quintana Method: A retrospective study carried out based on the search for cohort studies and Roo, Mexico clinical trials in the last 10 years in MEDLINE, EMBASE, and Cochrane Controlled Trials 2Mexican Institute Social Security Quintana Roo, Mexico Register whose keywords [Acute and Lymphoblastic Leukemia], [epigenetical], [Drug 3Professor at the University of Quintana Roo, Mexico Therapy], [Pediatric]. Correspondence: Maria Valeria Jiménez Baez, Av. Politécnico Results: 87 articles were found based on titles and abstracts, of which 16 focus on the Nacional s/n Entre Tepic and Kinic 77509 Cancun, University of age group and criteria of interest. Of the 10% of the known etiology, genetic alterations Quintana Roo, Mexico, Tel 9988742354, are more important. However, there are epigenetic modifications that are important for Email leukemia to occur, such as DNA methylation, histone modification, and regulation by non- coding RNAs. -
WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
HPV16 and HPV18 Type-Specific APOBEC3 and Integration Profiles
medRxiv preprint doi: https://doi.org/10.1101/2020.11.25.20238477; this version posted November 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 HPV16 and HPV18 type-specific APOBEC3 and integration profiles in different 2 diagnostic categories of cervical samples 3 4 Sonja Lagström1,2,3, Alexander Hesselberg Løvestad4, Sinan Uğur Umu2, Ole Herman 5 Ambur4, Mari Nygård2, Trine B. Rounge2,6,#,*, Irene Kraus Christiansen1,7,#,*, 6 7 Author affiliations: 8 1 Department of Microbiology and Infection Control, Akershus University Hospital, 9 Lørenskog, Norway 10 2 Department of Research, Cancer Registry of Norway, Oslo, Norway 11 3 Institute of Clinical Medicine, University of Oslo, Oslo, Norway 12 4 Faculty of Health Sciences, OsloMet - Oslo Metropolitan University, Oslo, Norway 13 5 Norwegian Cervical Cancer Screening Programme, Cancer Registry of Norway, Oslo, 14 Norway 15 6 Department of Informatics, University of Oslo, Oslo, Norway 16 7 Department of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus 17 University Hospital and University of Oslo, Lørenskog, Norway 18 19 20 #Equal contribution 21 *Corresponding authors 22 E-mail addresses: [email protected] (TBR), 23 [email protected] (IKC) 24 NOTE: This preprint reports new research that has not been certified1 by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.11.25.20238477; this version posted November 29, 2020. -
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Recommendations and Reports June 12, 2009 / Vol. 58 / No. RR-6 Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions INSIDE: Continuing Education Examination department of health and human services Centers for Disease Control and Prevention MMWR The MMWR series of publications is published by the Coordinating CONTENTS Center for Health Information and Service, Centers for Disease Introduction .............................................................................. 1 Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333. Background .............................................................................. 3 Suggested Citation: Centers for Disease Control and Prevention. CLIA Oversight for Molecular Genetic Testing ........................... 3 [Title]. MMWR 2009;58(No. RR-#):[inclusive page numbers]. Concerns Related to Molecular Genetic Testing ......................... 4 Centers for Disease Control and Prevention Richard E. Besser, MD Methods ................................................................................... 6 (Acting) Director Information Collection and Assessment ..................................... 6 Tanja Popovic, MD, PhD Development of CLIAC Recommendations for Good Chief Science Officer James W. Stephens, PhD Laboratory Practices in Molecular Genetic Testing ................ 6 Associate Director for Science Recommended Good Laboratory Practices ................................ -
Germline RUNX1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia
Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia Yizhen Li, … , Mignon L. Loh, Jun J. Yang J Clin Invest. 2021. https://doi.org/10.1172/JCI147898. Research In-Press Preview Genetics Oncology Graphical abstract Find the latest version: https://jci.me/147898/pdf 1 Germline RUNX1 Variation and Predisposition to Childhood Acute Lymphoblastic 2 Leukemia 3 Yizhen Li, PhD1* , Wentao Yang, PhD1*, Meenakshi Devidas, PhD2, Stuart S. Winter, MD3, 4 Chimene Kesserwan, MD4, Wenjian Yang, PhD1, Kimberly P. Dunsmore, MD5, Colton Smith, 5 PhD1, Maoxiang Qian, PhD 6, Xujie Zhao, MS1, Ranran Zhang, MS1, Julie M. Gastier-Foster, PhD7, 6 Elizabeth A. Raetz, MD8, William L. Carroll, MD8, Chunliang Li, PhD9, Paul P. Liu10, Karen R. 7 Rabin, MD, PhD11, Takaomi Sanda12,13, Charles G. Mullighan, MBBS, MD14, Kim E. Nichols, MD15, 8 William E. Evans, PharmD1,16, Ching-Hon Pui, MD15,16, Stephen P. Hunger, MD17, David T. 9 Teachey18, MD, Mary V. Relling, PharmD1,16, Mignon L. Loh, MD 19, Jun J. Yang, PhD1, 15, 16, # 10 1Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 2Department of Global 11 Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN, 3Children’s Minnesota Research Institute, 12 Children’s Minnesota, Minneapolis, MN, 4Center for Cancer Research, Genetics Branch, National Cancer Institute, 13 USA, 5Children’s Hematology and Oncology, Carilion Clinic and Virginia Tech Carilion School of Medicine, Roanoke, 14 VA, 6Children’s Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, China, 7Baylor College of 15 Medicine and Texas Children’s Hospital, Houston, TX, 8Division of Pediatric Hematology and Oncology, Perlmutter 16 Cancer Center, New York University Langone Health, New York, 9Tumor Cell Biology, St. -
Genetic and Genomics Laboratory Tools and Approaches
Genetic and Genomics Laboratory Tools and Approaches Meredith Yeager, PhD Cancer Genomics Research Laboratory Division of Cancer Epidemiology and Genetics [email protected] DCEG Radiation Epidemiology and Dosimetry Course 2019 www.dceg.cancer.gov/RadEpiCourse (Recent) history of genetics 2 Sequencing of the Human Genome Science 291, 1304-1351 (2001) 3 The Human Genome – 2019 • ~3.3 billion bases (A, C, G, T) • ~20,000 protein-coding genes, many non-coding RNAs (~2% of the genome) • Annotation ongoing – the initial sequencing in 2001 is still being refined, assembled and annotated, even now – hg38 • Variation (polymorphism) present within humans – Population-specific – Cosmopolitan 4 Types of polymorphisms . Single nucleotide polymorphisms (SNPs) . Common SNPs are defined as > 5% in at least one population . Abundant in genome (~50 million and counting) ATGGAACGA(G/C)AGGATA(T/A)TACGCACTATGAAG(C/A)CGGTGAGAGG . Repeats of DNA (long, short, complex, simple), insertions/deletions . A small fraction of SNPs and other types of variation are very or slightly deleterious and may contribute by themselves or with other genetic or environmental factors to a phenotype or disease 5 Different mutation rates at the nucleotide level Mutation type Mutation rate (per generation) Transition on a CpG 1.6X10-7 Transversion on a CpG 4.4X10-8 Transition: purine to purine Transition out of CpG 1.2X10-8 Transversion: purine to pyrimidine Transversion out of CpG 5.5X10-9 Substitution (average) 2.3X10-8 A and G are purines Insertion/deletion (average) 2.3X10-9 C and T are pyrimidines Mutation rate (average) 2.4X10-8 . Size of haploid genome : 3.3X109 nucleotides . -
Mouse Pip4k2a Conditional Knockout Project (CRISPR/Cas9)
https://www.alphaknockout.com Mouse Pip4k2a Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Pip4k2a conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Pip4k2a gene (NCBI Reference Sequence: NM_008845 ; Ensembl: ENSMUSG00000026737 ) is located on Mouse chromosome 2. 10 exons are identified, with the ATG start codon in exon 1 and the TAA stop codon in exon 10 (Transcript: ENSMUST00000006912). Exon 2 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Pip4k2a gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-346P16 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a null allele are viable and appear phenotypically normal. Exon 2 starts from about 11.93% of the coding region. The knockout of Exon 2 will result in frameshift of the gene. The size of intron 1 for 5'-loxP site insertion: 89699 bp, and the size of intron 2 for 3'-loxP site insertion: 1729 bp. The size of effective cKO region: ~598 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 2 3 10 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Pip4k2a Homology arm cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. -
Autism and Cancer Share Risk Genes, Pathways, and Drug Targets
TIGS 1255 No. of Pages 8 Forum Table 1 summarizes the characteristics of unclear whether this is related to its signal- Autism and Cancer risk genes for ASD that are also risk genes ing function or a consequence of a second for cancers, extending the original finding independent PTEN activity, but this dual Share Risk Genes, that the PI3K-Akt-mTOR signaling axis function may provide the rationale for the (involving PTEN, FMR1, NF1, TSC1, and dominant role of PTEN in cancer and Pathways, and Drug TSC2) was associated with inherited risk autism. Other genes encoding common Targets for both cancer and ASD [6–9]. Recent tumor signaling pathways include MET8[1_TD$IF],[2_TD$IF] genome-wide exome-sequencing studies PTK7, and HRAS, while p53, AKT, mTOR, Jacqueline N. Crawley,1,2,* of de novo variants in ASD and cancer WNT, NOTCH, and MAPK are compo- Wolf-Dietrich Heyer,3,4 and have begun to uncover considerable addi- nents of signaling pathways regulating Janine M. LaSalle1,4,5 tional overlap. What is surprising about the the nuclear factors described above. genes in Table 1 is not necessarily the Autism is a neurodevelopmental number of risk genes found in both autism Autism is comorbid with several mono- and cancer, but the shared functions of genic neurodevelopmental disorders, disorder, diagnosed behaviorally genes in chromatin remodeling and including Fragile X (FMR1), Rett syndrome by social and communication genome maintenance, transcription fac- (MECP2), Phelan-McDermid (SHANK3), fi de cits, repetitive behaviors, tors, and signal transduction pathways 15q duplication syndrome (UBE3A), and restricted interests. Recent leading to nuclear changes [7,8]. -
Structural Analysis of Cell Signaling Complexes Takuma Aoba Brigham Young University
Brigham Young University BYU ScholarsArchive All Theses and Dissertations 2016-12-01 Structural Analysis of Cell Signaling Complexes Takuma Aoba Brigham Young University Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Chemistry Commons BYU ScholarsArchive Citation Aoba, Takuma, "Structural Analysis of Cell Signaling Complexes" (2016). All Theses and Dissertations. 6583. https://scholarsarchive.byu.edu/etd/6583 This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in All Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Structural Analysis of Cell Signaling Complexes Takuma Aoba A dissertation submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Barry M. Willardson, Chair Gregory F. Burton Joshua L. Andersen Kenneth A. Christensen Joshua L. Price Department of Chemistry and Biochemistry Brigham Young University Copyright © 2016 Takuma Aoba All Rights Reserved ABSTRACT Structural Analysis of Cell Signaling Complexes Takuma Aoba Department of Chemistry and Biochemistry, BYU Doctor of Philosophy of Science Bardet-Biedl syndrome (BBS) is a rare genetic disease that causes retinal degradation, obesity, kidney dysfunction, polydactyly, and other cilium-related disorders. To date, more than 20 BBS genes, whose mutants cause BBS phenotypes, have been identified, and eight of those (BBS1-2, 4-5, 7-9, and 18) are known to form the BBSome complex. Recent studies have revealed that the BBSome is closely involved in the trafficking of signaling proteins in the primary cilium. -
Basis of Specificity for a Conserved and Promiscuous Chromatin
RESEARCH ARTICLE Basis of specificity for a conserved and promiscuous chromatin remodeling protein Drake A Donovan1, Johnathan G Crandall1, Vi N Truong1, Abigail L Vaaler1, Thomas B Bailey1, Devin Dinwiddie1, Orion GB Banks1, Laura E McKnight1*, Jeffrey N McKnight1,2 1Institute of Molecular Biology, University of Oregon, Eugene, United States; 2Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, United States Abstract Eukaryotic genomes are organized dynamically through the repositioning of nucleosomes. Isw2 is an enzyme that has been previously defined as a genome-wide, nonspecific nucleosome spacing factor. Here, we show that Isw2 instead acts as an obligately targeted nucleosome remodeler in vivo through physical interactions with sequence-specific factors. We demonstrate that Isw2-recruiting factors use small and previously uncharacterized epitopes, which direct Isw2 activity through highly conserved acidic residues in the Isw2 accessory protein Itc1. This interaction orients Isw2 on target nucleosomes, allowing for precise nucleosome positioning at targeted loci. Finally, we show that these critical acidic residues have been lost in the Drosophila lineage, potentially explaining the inconsistently characterized function of Isw2-like proteins. Altogether, these data suggest an ‘interacting barrier model,’ where Isw2 interacts with a sequence-specific factor to accurately and reproducibly position a single, targeted nucleosome to define the precise border of phased chromatin arrays. *For correspondence: [email protected] Introduction Chromatin consists of the nucleic acids and proteins that make up the functional genome of all Competing interests: The eukaryotic organisms. The most basic regulatory and structural unit of chromatin is the nucleosome. authors declare that no Each nucleosome is defined as an octamer of histone proteins, which is wrapped by approximately competing interests exist.